期刊
DRUG DISCOVERY TODAY
卷 16, 期 15-16, 页码 697-703出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2011.05.007
关键词
-
资金
- FDA's Critical Path Initiative
- Office of Women's Health
- Chief Scientist Challenge Grant
Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effective approach to discover key DILI mechanisms and risk factors. However, assessing the DILI potential of a drug is a challenge with no existing consensus methods. We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts. The method is transparent and reproducible with a potential to serve as a common practice to study the DILI of marketed drugs for supporting drug discovery and biomarker development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据